Treosulfan-Based Conditioning for Umbilical Cord Blood Recipients Is Safe and Effective: Results from an Ongoing Phase-II Study  by Milano, F. et al.
Poster Session II S337changes in transplant practices in the last decades also influenced the
decision to use TBI. This study explores the patterns and trends of
TBI use among HCT recipients worldwide.
Methods: 219,341 HCT recipients between 1995 and 2010 regis-
tered with the Center for International Blood and Marrow Trans-
plant Research (CIBMTR) from 596 centers in 52 countries were
analyzed. Subset analysis to investigate changes over time was per-
formed by excluding transplant centers that reported TBI use in all
(N 5 45) or in none (N 5 14,497) of the patients registered during
the period.
Results:TBI was utilized in 10% of autologous and 46% of alloge-
neic HCTs. Among autologous HCT recipients, TBI was most fre-
quently used in: patients of ages 10 to 29 years (10%), chronic
lymphocytic leukemia (56%), Middle East/ Africa (23%) and coun-
tries of medium Human Development Index (HDI) (46%). Among
allogeneic HCT recipients, TBI was most frequently used in: pa-
tients ages 10 to 39 years (45%), acute lymphocytic leukemia
(ALL) (80%), recipients of unrelated donor grafts (55%), Europe
(50%) and in countries with very high HDI. Utilization of TBI-
based conditioning decreased in both autologous (13% to 2%,
p\0.0001) and allogeneic HCTs (53% to 39%, p\0.0001) during
the study period. Decrease in TBI use was observed in all conti-
nents except in Latin America where use of TBI in allogeneic
HCT increased from 15 to 25% of transplants. Also, the drop in
TBI use was observed in all diseases, except in allogeneic HCTs
for ALL (74% to 84%, p\0.0001). Among patients with ALL,
TBI use over time increased in pediatric patients (75% to 91%,
p\0.0001) and recipients of sibling donor grafts (69% to 78%,
p\0.0001).
Discussion: Variations in use of TBI were mainly observed by age,
geographic regions, HDI, cell sources, and disease indications. Use
of TBI decreased significantly over time with exception of allogeneic
HCTs for patients with ALL.358
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Backgrounds:Treosulfan (Treo) is an immuno-suppressive and cy-
totoxic alkylating agent recently introduced as a conditioning agent
for hematopoietic cell transplantation (HCT). Previous studies have
evaluated the use of Treo-based conditioning regimens for conven-
tional donorHCT, however, there is minimal experience using Treo
in umbilical cord blood transplantation (CBT).
Methods: Between March 2009 and July 2011, 25 consecutive CBT
recipients were enrolled in a prospective phase II study at Fred
Hutchinson Cancer Research Center. All patients received intrave-
nous (IV) fludarabine, 30 mg/m2 on days -6 to -2 (total dose: 150
mg/m2), Treo 14 g/m2 IV on days -6, -5, and -4 (total dose: 42
g/m2) and a single dose of 2 Gy of total body irradiation (TBI) on
day -2 before HCT. Graft Versus Host Disease (GVHD) prophy-
laxis consisted of cyclosporine and MMF. Engraftment, non-relapse
mortality (NRM) and acute and chronic GVHD were calculated us-
ing cumulative incidence (CI) rates. Relapse-free survival (RFS) and
overall survival (OS) were determined using Kaplan-Meier
estimates.
Results: All but 2 patients received double CBT, and the median
dose of nucleated cells was 3.8 (range, 2.4-11.2) x 107/Kg. The me-
dian age was 48 (range, 5-63) years and weight 76 (range, 17-114)
Kg. Eighteen patients (72%) had acute leukemia, 5 (20%) MDS
and 2 CML (8%). Four patients (16%) had received a previous al-
logeneic and 1 a previous autologous HCT. Fifteen patients (60%)
had minimal residual disease, and 6 (24%) were in second complete
remission (CR2). The median follow-up of survivors was 435 (range
73-947) days. Median time of neutrophil recovery was 23 (range,
13-89) days, with a CI of engraftment of 92% (95% CI, 72-97%).
Two patients experienced primary graft failure, and one of these re-
ceived a second HLA-haploidentical HCT. The 2-year probabili-ties of OS and RFS were 61.7% (95% CI, 37-79%) and 54%
(95% CI, 28-74%), respectively. The CI of NRM at 2 years was
18% (95% CI, 5-37%), and relapse incidence 21% (6-43%). Eight
patients (32%) died, relapse and multiorgan failure being the most
common causes (n 5 6). The CI of grades II-IV and III-IV acute
GVHD was 64% (95% CI, 42-80) and 20% (95% CI, 7-38%), re-
spectively. Chronic incidence GVHD at 1 year was 28% (95% CI,
10-45%).
Conclusions: Data from this trial suggest that Treo-based condi-
tioning regimens are safe and effective in CBT. Treo represents
a promising non-TBI based myeloablative regimen for patients un-
dergoing CBT.359
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Background: The effect of sex mismatch on outcome in allogeneic
hematopoietic stem cell transplantation (HSCT) has been studied
with controversial results. Possible effect of Y chromosome mis-
match in graft-versus-host (GVH) direction, i.e. HSCT from a fe-
male donor to a male recipient has been identified in previous
studies. HSCT from a Japanese donor to a Japanese recipient is re-
ported to have lower incidence of severe acute GVHD and lower
mortality which may derive from their genetic homogeneity back-
ground. Therefore, the effect of Y chromosome mismatch may be
clearer in our population.
Purpose:The aim of this study is to assess the effect of sex mismatch
on outcome in allogeneic HSCT.
Method: Sixty-four hundred twenty-one adult patients (3,768
males and 2,653 females) with a median age of 45-year-old (range
16-82) who underwent allogeneic HSCT for the first time for he-
matological malignancies between January, 2006 and December,
2009 in Japan were included in this study. 4,121 patients (64%)
had acute leukemia as underlying disease. Bone marrow transplan-
tation (BMT) (62%), peripheral blood stem cell transplantation
(PBSCT) (21%), and cord blood transplantation (CBT) (17%)
were all included. Sixty-three percent were from unrelated donors.
Data were collected and analyzed retrospectively using the trans-
plant outcome database of Japan Society for Hematopoietic Cell
Transplantation.
Results: Proportion of female to male donor-recipient pairs (F to
M mismatch) were 23% (n 5 1,500) (53%, n 5 3,401 for sex-
matched pairs and 24%, n 5 1,520 for male to female pairs). Pro-
portion of peripheral blood (24% vs. 19%) and cord blood (23% vs.
16%) was larger in F to M mismatch (p\0.001). More patients re-
ceived human leukocyte antigen (HLA) -A, -B, and -DR serological
mismatched graft in F to M mismatch (35% vs. 29%, p\0.01). In
univariate comparison, the probabilities of overall survival (OS)
was significantly lower in F to M mismatch (p\0.001). Although
the effect of F to M mismatch on OS was more obvious in HLA-
matched HSCT (p 5 0.0033), it was also observed in HLA-mis-
matched HSCT (p 5 0.017). The probabilities of OS in F to M
mismatch was significantly lower in unrelated BMT (p 5 0.011)
and CBT (p 5 0.019). However, there was no significantly differ-
ence among related BMT (p 5 0.087) and PBSCT (p 5 0.54) ac-
cording to the presence of F to M mismatch, even if HSCT were
limited to HLA-matched.
Conclusion: Female to male sex mismatch has a significant impact
on the outcome of HSCT.
